title: Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188.
abstract: Mopidamol (RA-233), a derivative of dipyridamole, is a phosphodiesterase inhibitor that has been shown previously to limit progression of malignancy in certain experimental animal models and in a pilot study in humans. RA-233 plus chemotherapy was compared with chemotherapy alone in a 5-year double-blind trial involving 719 patients with advanced carcinomas of the lung and of the colon. RA-233 treatment was associated with a statistically significant prolongation of survival in patients with non-small cell lung cancer (N-SCLC) limited to one hemithorax and with reduction in mean plasma fibrogen concentration. RA-233 was not toxic. The favorable effects on survival could not be explained by any factor other than the RA-233 treatment. In other tumor categories tested, no differences in survival were observed. These results suggest that RA-233 is useful in the treatment of N-SCLC of limited extent. They also suggest that therapeutic intervention aimed at modified intracellular pathways might constitute a novel investigative approach to the treatment of cancer.
authors.affiliation: Veterans Administration (VA) Medical Center, White River Junction, VT 05001.
authors.forename: L R
authors.initials: LR
authors.lastname: Zacharski
authors.forename: T E
authors.initials: TE
authors.lastname: Moritz
authors.forename: L A
authors.initials: LA
authors.lastname: Baczek
authors.forename: F R
authors.initials: FR
authors.lastname: Rickles
authors.forename: R L
authors.initials: RL
authors.lastname: Edwards
authors.forename: W B
authors.initials: WB
authors.lastname: Forman
authors.forename: R J
authors.initials: RJ
authors.lastname: Forcier
authors.forename: C J
authors.initials: CJ
authors.lastname: Cornell
authors.forename: C M
authors.initials: CM
authors.lastname: Haakenson
authors.forename: H S
authors.initials: HS
authors.lastname: Ballard
mesh_terms: D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D000242:Cyclic AMP / Q000032:analysis; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009012:Mopidamol / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009857:Oncogenes; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D011897:Random Allocation
chemical_list: D011743:Pyrimidines; D009012:Mopidamol; D000242:Cyclic AMP